Crinetics Pharmaceuticals

Do you know someone living with carcinoid syndrome? Learn more about our Phase 3 clinical trial in adults with #CarcinoidSyndrome due to neuroendocrine tumors. Sign up to receive important updates here: https://carefndr.com/

We are excited to welcome Isabel Kalofonos as our new Chief Commercial Officer! Isabel will lead our global commercial strategy and operations for our first new drug launch, as well as pre-commercialization activities for our innovative pipeline of candidates.

At Crinetics, we believe that happy pets make for happy people — and that’s why we’re proud to offer a dog-friendly workplace! Our four-legged companions bring joy, reduce stress, and create a unique, collaborative atmosphere where both employees and their pups can thrive together. From tail wags to team success, we know that a positive work environment benefits everyone, fur babies included! Ready to join a team where you and your pup can flourish? Explore our open positions here: https://bit.ly/3BmigiR #hiring #careers

We are excited to share that the U.S. Food and Drug Administration has accepted our New Drug Application for an investigational treatment for acromegaly in adults. We are grateful for the dedication of our team and the continued support of the acromegaly community throughout this journey! Learn more about this milestone: https://bit.ly/4g5dB3N

Living with carcinoid syndrome means managing daily challenges that impact quality of life, from persistent flushing and diarrhea to serious heart complications. The current standard of care is burdensome, involving depot injections of somatostatin peptide analogs that are associated with injection pain, inconsistent exposure, and breakthrough symptoms. At Crinetics, we are advancing research on an investigational, once-daily, nonpeptide, oral selective SST2 agonist, which is being studied for its potential to address the needs of patients with #CarcinoidSyndrome. Learn more: https://bit.ly/4cTcdzP  

Today, we will be presenting Phase 2 data on our investigational #CarcinoidSyndrome drug candidate during an oral presentation at the 2024 NANETS NET Medical Symposium. Join us to hear updates on our ongoing research into potential treatment options for this complex condition. Learn more about an upcoming Phase 3 trial by visiting CAREFNDR.com

We're excited to share preclinical data for a potentially first-in-class, nonpeptide drug conjugate candidate in development for neuroendocrine tumors. Join us at 5:15 pm CT to discover our latest research. If interested in more information on our clinical trial program, contact us here: https://lnkd.in/gqwdFKX8

Be part of the conversation at the 2024 NANETS NET Symposium and learn more about our exciting research updates. Stop by the Crinetics Symposium from 12:15-1:15 pm CT in Salon E to learn about our nonpeptide drug conjugate platform and Phase 3 trial details for our carcinoid syndrome candidate. If interested in more information on our clinical trial program, contact us here: https://lnkd.in/gqwdFKX8 #NeuroendocrineTumor

We are excited to join NANETS for the 2024 Multidisciplinary NET Medical Symposium. This annual event brings together leading experts, researchers, and healthcare professionals to explore the latest advancements in neuroendocrine tumor (NET) diagnosis and treatment. At Crinetics, we’re committed to improving patient outcomes and advancing care in the NET community. We look forward to engaging with colleagues and sharing insights that shape the future of NET treatment.

We’re pleased to welcome Samer Saadeh, General Manager, Europe who joined Crinetics as our first European-based employee. Samer will lead our European organization based in Zug, Switzerland, in the development and commercialization of our medicines in Europe. We look forward to continuing to build our global team.